New York-based Expertise Added for Capital Raise and Financing Strategies and Regenerative Medicine Organ Development and Transplantation Program
ST. PAUL, Minn. Recombinetics (RCI), a pioneer in gene editing solutions for human health and animal agriculture, today announced two new appointments to its governance and strategic advisory boards.
“The addition of Jim Kilman to our Board of Directors adds depth and expertise to our capital raise and financing capabilities. The selection of Dr. Robert Montgomery to lead our regenerative medicine advisory board accelerates our ability to develop human cells, tissues, and organ products in our gene-edited swine models for human transplantation,” said Tammy Lee Stanoch, President, and CEO of Recombinetics. “These appointments advance our strategy to develop a strong East Coast presence and partner with leading financial and medical institutions to drive our business forward.”
Jim Kilman is Chief Executive Officer of KielStrand Capital, a family office/merchant bank based in Scarborough, New York that makes and manages investments, provides advice and engages in philanthropic activities. Prior to forming KielStrand Capital in 2016, Jim retired as Vice Chairman of Investment Banking at Morgan Stanley. Kilman spent 32 years in the investment banking business, including senior roles at Goldman Sachs, ABN AMRO, and PaineWebber. Kilman currently serves as Vice Chairman of the Board of alpha-En Corporation, a publicly-traded provider of lithium metal technology in Yonkers, NY and as Senior Advisor at Burford Capital Ltd, a London-listed global finance firm focused on law. He holds an M.A. and a B.A. in Economics from Yale University.
Dr. Robert Montgomery is a renowned transplantation surgeon, having performed more than 1,000 kidney transplants. As the Director of the NYU Langone Transplant Institute, Dr. Montgomery oversees a team of medical and surgical specialists providing a wide range of transplantation services. Dr. Montgomery is widely considered the world’s leading authority on “desensitization,” a process that readies patients to receive incompatible tissue or blood transplants. This expertise is indispensable for Recombinetics’ regenerative medicine division, Regenevida, where swine models are gene-edited to incubate human cells, tissues and organs for use in transplantation for patients. Dr. Montgomery will serve as the lead director for Regenevida.
In addition to these two New York-based appointments, Dr. Jef Boeke serves on the Recombinetics Scientific Advisory Board. Dr. Boeke is widely recognized expert in yeast genetics, a model organism platform for developing compounds, medicines, and vaccine. At NYU Langone Health, Dr. Boeke is the Director of NYU Langone Institute for Systems Genetics and a Professor in the Department of Biochemistry and Molecular Pharmacology. Dr. Boeke is leading an international initiative to create an entire synthetic genome which has already constructed a synthetic chromosome of Brewer’s yeast. As a member of Recombinetics’ Scientific Advisory Board, he will contribute additional expertise to Regenevida in collaboration with Dr. Bob Montgomery.
Learn more about a “dream team’s” effort to grow a human kidney in a pig lead by Drs. Montgomery, Boeke, the Recombinetics team and others: